Cancer of Unknown Primary Site Unknown Status Phase 2 Trials for Ipilimumab (DB06186)
| Indication | Status | Phase |
|---|---|---|
| DBCOND0089665 (Cancer of Unknown Primary Site) | Unknown Status | 2 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT04131621 | Nivolumab/Ipilimumab in Second Line CUP-syndrome | Treatment |